Sprenger, Jana

[["dc.bibliographiccitation.firstpage","550"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","British Journal of Surgery"],["dc.bibliographiccitation.lastpage","557"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Helms, H.-J."],["dc.contributor.author","Lordick, Florian"],["dc.contributor.author","Rueschoff, Josef"],["dc.contributor.author","Conradi, L.-C."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Thorsten"],["dc.date.accessioned","2018-11-07T09:41:56Z"],["dc.date.available","2018-11-07T09:41:56Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Multidisciplinary discussion of the treatment of patients with colorectal liver metastases (CRLM) is advocated currently. The aim of this study was to investigate medical oncologists' and surgeons' assessment of resectability and indication for chemotherapy, and the effect of an educational intervention on such assessment. Methods: Medical histories of 30 patients with CRLM were presented to ten experienced medical oncologists and 11 surgeons at an initial virtual tumour board meeting (TB1). Treatment recommendations were obtained from each participant by voting for standardized answers. Following lectures on the potential of chemotherapy and surgery, assessment was repeated at a second virtual tumour board meeting (TB2), using the same patients and participants. Results: Overall, 630 answers (21 x 30) were obtained per tumour board meeting. At TB1, resectability was expected more frequently by surgeons. Participants changed 56.8 per cent of their individual answers at TB2. Assessment shifted from potentially resectable to resectable CRLM in 81 of 161 and from unresectable to (potentially) resectable CRLM in 29 of 36 answers. Preoperative chemotherapy was indicated more often by medical oncologists, and overall was included in 260 answers (41.3 per cent) at TB1, compared with only 171 answers (27.1 per cent) at TB2. Medical oncologists more often changed their decision to primary resection in resectable patients (P = 0.006). Postoperative chemotherapy was included in 51.9 and 52.4 per cent of all answers at TB1 and TB2 respectively, with no difference in changes between medical oncologists and surgeons (P = 0.980). Conclusion: Resectability and indication for preoperative chemotherapy were assessed differently by medical oncologists and surgeons. The educational intervention resulted in more patients deemed resectable by both oncologists and surgeons, and less frequent indication for chemotherapy."],["dc.description.sponsorship","Merck Serono GmbH, Germany"],["dc.identifier.doi","10.1002/bjs.9436"],["dc.identifier.isi","000332700100017"],["dc.identifier.pmid","24756914"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33842"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1365-2168"],["dc.relation.issn","0007-1323"],["dc.title","Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","191"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Current Medicinal Chemistry"],["dc.bibliographiccitation.lastpage","199"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Reichert, S."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Gaipl, U. S."],["dc.contributor.author","Mirsch, J."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Fulda, S."],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T09:01:04Z"],["dc.date.available","2018-11-07T09:01:04Z"],["dc.date.issued","2011"],["dc.description.abstract","Alterations in the expression of apoptosis-related proteins, like the inhibitor of apoptosis (IAP) protein family, display a pivotal pathway by which cancer cells acquire resistance to therapeutic treatment. Among this family, survivin, the smallest and structural unique member, deserves growing attention due to its universal over-expression in human tumors, and its prominent role in disparate networks of cellular division, intracellular signaling and apoptosis. Several preclinical studies have demonstrated that targeting survivin expression by the use of small interfering RNAs, dominant negative mutants, antisense-oligonucleotides and small molecule repressors sensitized tumor cells towards chemotherapy and irradiation and reduced tumor growth potential. Due to these properties, survivin has been proposed as a molecular target for anticancer therapies. Recent studies further revealed that radio-sensitization achieved by survivin inhibition seems to be multifaceted and involves caspase-dependent and caspase-independent mechanisms. In general, an enhanced rate of apoptosis, and pronounced cell cycle arrest have been observed. More recently, a hampered DNA-damage response has been noted, indicating a distinct role of the protein in radiation-induced double strand break repair. These properties were linked to a nuclear import and physical interrelationship with members of the DNA-DSB repair machinery such as phospho-histone H2AX and DNA dependent Protein Kinase (DNA-PKcs). The applicability of survivin-driven strategies in clinical practice is currently under investigation as the first survivin inhibitors successfully entered phase I/II trials. Although these trials do not include radiation therapy at present, survivin inhibitors may represent a novel type of molecular antagonists to improve the effectiveness of radiation therapy or chemoradio-therapy."],["dc.identifier.doi","10.2174/092986711794088362"],["dc.identifier.isi","000286588800003"],["dc.identifier.pmid","21110807"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24326"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bentham Science Publ Ltd"],["dc.relation.issn","0929-8673"],["dc.title","The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","435"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","435"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H. A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","435 Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of 3/ 3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.435"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110056"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S430"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Conradi, L.C."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H.A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B.M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:58:33Z"],["dc.date.available","2022-06-08T07:58:33Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1016/S0959-8049(11)71771-3"],["dc.identifier.pii","S0959804911717713"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110450"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.issn","0959-8049"],["dc.title","6126 POSTER Thymidylate Synthase as Biomarker in Rectal Cancer Patients After 5-FU-based Radiochemotherapy – Evaluation of the Prognostic Capacity in Pre-treatment Biopsies and Resected Adenocarcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S431"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rödel, F."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L.C."],["dc.contributor.author","Yildirim, M."],["dc.contributor.author","Ghadimi, B.M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:58:33Z"],["dc.date.available","2022-06-08T07:58:33Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1016/S0959-8049(11)71775-0"],["dc.identifier.pii","S0959804911717750"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110451"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.issn","0959-8049"],["dc.title","6130 POSTER Survivin Expression in Rectal Cancer During Preoperative Radiochemotherapy and Its Impact on Metastasis and Patients' Survival"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e14115"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","e14115"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rodel, F."],["dc.contributor.author","Rothe, H."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:18Z"],["dc.date.available","2022-06-08T07:57:18Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1200/jco.2010.28.15_suppl.e14115"],["dc.identifier.isi","000208852000619"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110052"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Survivin: A potential predictive and prognostic marker in multimodal rectal cancer therapy."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","483"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","483"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rödel, F."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Yildrim, M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","483 Background: Valid molecular markers need to be implemented in clinical trials to fulfill the demand of a risk-adapted and more individualized multimodal therapy of locally advanced primary rectal cancer. In the present study the expression of the inhibitor-of-apoptosis (IAP) protein Survivin was evaluated in pre-treatment biopsies and corresponding post-treatment resection specimens, and was correlated to histo-pathological tumor characteristics and clinical follow-up. Methods: 116 patients with stage II/III rectal cancer treated with 5-FU-based neoadjuvant radiochemotherapy (RCT) within the German Rectal Cancer Trials were investigated. Survivin expression in pre-treatment biopsies and surgical resection specimens were determined by immunohistochemistry by two independent institutions and correlated with histopathologic parameters, tumor recurrences, disease-free and overall cancer-specific survival. Results: In pre-treatment biopsies, a higher Survivin expression correlated with advanced ypT (p=0.026) and ypUICC (p=0.05) stage as well as decreased disease-free survival (p=0.038) after preoperative RCT. High post-treatment Survivin levels were associated with advanced ypT stage (p=0.03) and residual lymph node metastases (p=0.04). Moreover, neoadjuvant RCT resulted in a significant down-regulation of Survivin expression (p < 0.0001). A failure of RCT-induced down-regulation was associated with development of distant metastases (p=0.0056) and cancer-related death (p=0.026), and was significantly correlated with disease-free (p=0.011 /0.02 ) and cancer-specific survival (p=0.0017 /0.01 ) in uni - and multivariate analyses. Conclusions: Survivin expression displays a marker with prognostic validity in rectal cancers. These results underline the usefulness of Survivin to monitor individual response to RCT in rectal cancer, and encourage anti-Survivin strategies in multimodal rectal cancer therapy within future randomised clinical trials. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110057"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Association of survivin expression following neoadjuvant radiochemotherapy in rectal cancer with distant metastases and survival."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","779"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Der Onkologe"],["dc.bibliographiccitation.lastpage","788"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T08:41:01Z"],["dc.date.available","2018-11-07T08:41:01Z"],["dc.date.issued","2010"],["dc.description.abstract","Based on the results of the CAO/ARO/AIO-94 trial of the German Rectal Cancer Study Group preoperative 5-FU-based radiochemotherapy (RCTx) is recommended as the standard treatment of locally advanced rectal cancers (UICC stages II and III) of the middle and lower third of the rectum (0-12 cm above the anocutaneous margin). Unfortunately, tumor response to neoadjuvant RCTx is very heterogeneous ranging from complete pathological response (pCR) to total resistance. To fulfill the clinical requirement of an individualized and risk-adapted multimodal treatment, progress has been made in genomic and proteomic analyses of cellular signaling pathways. Compared with postoperatively determined clinicopathological parameters of local response, complex phenotypes, such as tumor responsiveness to RCTx do not depend on the expression levels of just one or a few genes and proteins. Therefore, methods which allow comprehensive interrogation of genetic pathways and networks hold great promise in delivering tumor-specific signatures, because expression levels of tens of thousands of genes can be monitored simultaneously. During the past few years microarray technology has emerged as the key tool in addressing pertinent clinical questions, the answers to which are critical for the realization of personalized genomic medicine, in which patients will be treated based on the biology of the tumor and the genetic profile."],["dc.identifier.doi","10.1007/s00761-010-1866-y"],["dc.identifier.isi","000281289000007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19377"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0947-8965"],["dc.title","Molecular markers for response prediction in locally advanced rectal cancer. Is individualized therapy coming?"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1359"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1367"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T09:05:22Z"],["dc.date.available","2018-11-07T09:05:22Z"],["dc.date.issued","2012"],["dc.description.abstract","Bilobar colorectal liver metastases (CRLM) are often considered incurable or associated with poor prognosis even after R0 resection. In this single-center study, we evaluate the impact of CRLM spreading on recurrence-free survival (RFS) and cancer-specific overall survival (CSS) after R0 resection of CRLM with respect to multimodal treatment strategies including perioperative chemotherapy and multistep resections. Between January 2001 and December 2010, R0 resection could be achieved in 70 patients with bilobar and 100 with unilobar CRLM. Extent of disease, perioperative chemotherapy, surgical procedures, adjuvant treatment, histopathological workup, RFS, and CSS were compared between both cohorts. Forty-six (66 %) patients with bilobar and 26 (26 %) patients with unilobar CRLM received preoperative chemotherapy (p < 0.001). For bilobar CRLM, more extended and multistep resection including portal vein occlusion were performed (29 % versus 3 %; p < 0.001). Morbidity (39 % versus 28 %, p = 0.183) and mortality (1 % versus 3 %, p = 0.644) rates were comparable in both patients' cohorts. Postoperative therapy was applied in adjuvant intent to 42 (60 %) versus 51 (51 %) patients (p = 0.275). The 5-year RFS and CSS rates were 24 % versus 31 % (p = 0.169) and 42 % versus 55 % (p = 0.131), respectively. To our single-center experience, there is no significant effect of CRLM spreading (bilobar versus unilobar) on RFS and CSS rates. Bilobar CRLM are more likely to require extended multimodal efforts to achieve R0 resection."],["dc.identifier.doi","10.1007/s00384-012-1455-1"],["dc.identifier.isi","000309171200014"],["dc.identifier.pmid","22430890"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25298"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1009"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1017"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T09:23:05Z"],["dc.date.available","2018-11-07T09:23:05Z"],["dc.date.issued","2013"],["dc.description.abstract","Surgery is the standard of care for resectable colorectal liver metastases (CRC-LM). Unfortunately, 60 % of patients develop secondary metastatic recurrence (SMR) after R0-resection of CRC-LM. We investigated the impact of surgical re-intervention and chemotherapy (Ctx) on survival in a consecutive series of patients with SMR. From 01/2001 to 11/2011, 104 out of 178 consecutive patients with R0-resection of CRC-LM developed SMR and were evaluated. The impact of surgical and Ctx re-interventions on recurrence free (RFS) and cancer-specific survival (CSS) was analyzed. Median follow-up was 28.0 (95 %CI: 19.4-37.4) months. SMR occurred in 81 patients at a single site (49x liver, 18x lung, 14x other) and in 23 patients at multiple sites. Forty-two patients were scheduled for primary surgery. Fifty-three patients were classified as non-resectable and treated with median 5.0 [IQR, 3.0-10.0] cycles of Ctx, combined with an EGFR/VEGF-antibody in 27 patients. Nine patients received best supportive care only. R0/R1 resection could be achieved in 35 patients primarily and even in 8 patients secondarily after Ctx. Surgical morbidity and mortality were 16 and 0 %, respectively. The 5-year RFS rates for patients with R0 versus R1-resection were 22 and 24 % (p = 0.948). The 5-year CSS rate for R0/R1-resected patients was 38 % versus 10 % for those patients treated by Ctx alone (p < 0.001). In SMR, surgical re-intervention is feasible and safe in a remarkable number of patients and offers significantly longer CSS compared to patients without resection."],["dc.identifier.doi","10.1007/s00384-013-1648-2"],["dc.identifier.isi","000321912200014"],["dc.identifier.pmid","23371333"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10297"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29498"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]